Key facts
- This page summarizes Angus Grant's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Aug 2024, 16:06.
Angus Grant - 09 Aug 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- EVP, Business Development
- Issuer ticker
- TEVA
- Reported as of
- 09 Aug 2024
- Net transaction value
- -$70,243
- SEC form
- 4
- Accepted by SEC
- 13 Aug 2024, 16:06:50 UTC
- Prior SEC filing
- 05 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Angus Grant
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Angus Grant filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 13 Aug 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: -$70,243.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +12,913
- Change %
- Price
- Shares after
- 12,913
- Date
- 09 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
TEVA
transaction
Ordinary Shares
Sale
- Transaction value
- $70,243
- Shares
- -4,065
- Change %
- -31%
- Price
- $17.28
- Shares after
- 8,848
- Date
- 09 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TEVA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -12,913
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 38,739
- Date
- 09 Aug 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 12,913
- Exercise price
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F3
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024.
Footnote F4
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
Footnote F5
Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027.